Clinical Trial

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-20; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2026-03-20
Trial Details
NCT Number NCT07145177
Lead Sponsor University of California, San Francisco
Collaborators: Novartis
Conditions Metastatic Prostate Cancer, Prostate Cancer
Enrollment 30 participants
Start Date 2026-03-16
Primary Completion 2028-10-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01